Fact Source: Financial Supervisory Service DART / 2025-10-23
Disclosure Type: Suspension and Resumption of Trading for Stock Futures and Options
💡 3-Second Summary
Following an upcoming market action on the underlying asset, trading for Samsung Biologics stock futures and stock options will be suspended effective October 30, 2025, with the resumption date currently undecided.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Target Products: Samsung Biologics Stock Futures and Stock Options
- Trading Suspension Date: October 30, 2025
- Trading Resumption Date: Undetermined (Indicated as ‘–‘ in the original text)
- Reason for Suspension: Trading suspension of the underlying asset
- Governing Regulation: Article 74 of the Enforcement Rules of the Derivatives Market Business Regulation
- Note: This specific filing does not provide a scheduled resumption date, as the timeline remains linked to the market action taken on the underlying common stock.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing indicates a temporary halt in trading for the derivative products (stock futures and options) tied to Samsung Biologics. Rather than representing a shift in the company’s operational performance or revenue metrics, this action serves as a regular regulatory adjustment.
The primary point for market participants to register is that the suspension takes effect on October 30, 2025, and is directly triggered by the trading halt of the underlying common stock. As this is an institutional linkage governed by derivatives market enforcement rules, investors should review the separate disclosures concerning the underlying stock to identify the primary cause and expected duration of the common stock halt. This specific text does not specify the underlying reasons or timelines regarding the common stock’s suspension.
In conclusion, the schedule for the derivatives trading halt is verified through this filing. Because the resumption timeline remains blank, market participants trading these derivative instruments should check subsequent updates regarding the lifting of the underlying asset’s suspension to monitor when trading is likely to return.
📝 Editor’s Comment (by K-STOCK Editor)
Investors holding positions or planning to adjust exposure in Samsung Biologics stock futures and options must register the fact that trading will be halted starting October 30, 2025. This suspension is a structural procedure that automatically ties the derivative instruments to the status of the underlying common stock. Currently, the explicit reason for the underlying stock’s halt and its exact resumption date are not detailed within this text. Market participants should avoid looking at the derivatives data in isolation and instead follow subsequent disclosures regarding the underlying equity to manage portfolio risks appropriately.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
